Category Archives: Special 301 report

‘Big Pharma’ backs Trump’s Asia trade squeeze

Source: ASIA TIMES | May 03, 2018 US President Donald Trump’s administration stands accused of deploying bullying tactics to promote greater market access for American pharmaceutical companies by stifling the production and distribution of more affordable, and usually totally legal, … Continue reading

Posted in Special 301 report, US Pressure, USTR 301 report | Leave a comment

LIES, DISTORTIONS, AND FALSE PROMISE: THE U.S. POSITION ON COMPULSORY LICENSES IN THE 2018 SPECIAL 301 REPORT

Source: infojustice.org | May 1, 2018 Every year since the late 1980s, the U.S. has published a Special 301 Watchlist targeting countries that U.S. intellectual property-based industries, like Big Pharma, complain about. Once again the U.S. is unbelievably duplicitous in its 2018 … Continue reading

Posted in Special 301 report, USTR, USTR 301 report | Leave a comment

Why India may not be able to ignore USTR’s 2018 Special 301 report

Source : Business Line | May 1, 2018 The United States Trade Representative has, in its “2018 Special 301 Report”, placed India on the “priority watch list”, again. A move that has been labelled ‘anti public health’ by international humanitarian … Continue reading

Posted in Special 301 report | Leave a comment

USTR Priority Watch List calls out countries for protecting public health

Source: MSF Access | April 27, 2018 NEW YORK, APRIL 27, 2018-The Office of the United States Trade Representative (USTR) released its annual “Special 301 Report” today, which reviews countries based on their intellectual property (IP) rights protection and enforcement. … Continue reading

Posted in Special 301 report, USTR, USTR 301 report | Leave a comment

The scalpels are out ahead of ‘Special 301’ Report

 by PT Jyothi Datta | The HinduBusinessLine Indian pharma pushes back against US trade body’s criticism of its IPR protection record For the past five years, a lone Indian pharmaceutical representation goes out to the Office of the US Trade … Continue reading

Posted in IPR, Special 301 report, Uncategorized | Leave a comment

Section 301: US investigates allegations of forced technology transfers to China

Source: EastAsia Forum Authors: Zhiyao (Lucy) Lu and Gary Clyde Hufbauer, Peterson Institute for International Economics On 18 August 2017, the Trump administration invoked Section 301 of the Trade Act of 1974 to launch an investigation into alleged Chinese violations of intellectual … Continue reading

Posted in Seizures, Special 301 report, Uncategorized, WTO | Leave a comment

The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest

Source: Medium Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six page document outlining the draft provisions or objectives of a proposed Presidential Executive Order (EO) on drug prices. She has shared some of … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment